Warning for Rx smoking-cessation drugs
This article was originally published in The Tan Sheet
Executive Summary
OTC products could see prescription users switching after FDA requires warnings on Rx smoking-cessation drugs about the risk of serious mental health events including behavior changes, depressed mood, hostility and suicidal thought. The agency July 1 said boxed warnings must be added to the prescribing information for Pfizer's Chantix (varenicline) and GlaxoSmithKline's Zyban (bupropion hydrochloride). FDA, which also required similar information for bupropion marketed as the antidepressant Wellbutrin and generics, based its decision on a review of adverse event reports submitted and an analysis of clinical trials and scientific literature. Smoking-cessation OTC manufacturers, including GSK with Nicorette gum, NicoDerm patches and Commit lozenges, could use this warning to promote the safety of its products. In mid 2008 GSK advertised its OTC products were not linked to FDA's warning that use of Chantix has been linked to psychiatric adverse events (1"The Tan Sheet" June 30, 2008)
You may also be interested in...
GSK Lights Fire Under Educating Consumers On Smoking Cessation OTCs
GlaxoSmithKline says it is stepping up public relations efforts to tell consumers that its OTC smoking cessation products are not linked to problems reported with Pfizer's Rx drug Chantix
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.